|
SLC30A9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.26196839037129E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.46753745109163E-12 |
| Normal-vs-Stage2 |
6.589800E-04 |
| Normal-vs-Stage3 |
8.81430484156454E-11 |
| Normal-vs-Stage4 |
1.09320330565765E-11 |
| Stage1-vs-Stage2 |
5.796100E-02 |
| Stage1-vs-Stage3 |
2.681000E-01 |
| Stage1-vs-Stage4 |
4.975600E-02 |
| Stage2-vs-Stage3 |
2.301600E-02 |
| Stage2-vs-Stage4 |
4.058800E-03 |
| Stage3-vs-Stage4 |
2.969800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.12923037376822E-14 |
| Normal-vs-AfricanAmerican |
7.378600E-04 |
| Normal-vs-Asian |
8.72070005097925E-09 |
| Caucasian-vs-AfricanAmerican |
1.937580E-01 |
| Caucasian-vs-Asian |
7.391000E-01 |
| AfricanAmerican-vs-Asian |
1.876020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60980118124598E-11 |
| Normal-vs-Female |
1.14559473018971E-11 |
| Male-vs-Female |
2.303600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.26679794326878E-11 |
| Normal-vs-Age(41-60Yrs) |
1.18639542634469E-11 |
| Normal-vs-Age(61-80Yrs) |
2.89379999962591E-08 |
| Normal-vs-Age(81-100Yrs) |
1.364380E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.306000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.650200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.537800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.093200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.651800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.988600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.356300E-02 |
| Classical-VS-Follicular |
1.038770E-01 |
| Classical-VS-Other |
1.824210E-01 |
| Classical-VS-Normal |
2.7237101463129E-12 |
| Tall-VS-Follicular |
4.162100E-03 |
| Tall-VS-Other |
5.026400E-01 |
| Tall-VS-Normal |
7.10089764766053E-11 |
| Follicular-VS-Other |
1.267770E-01 |
| Follicular-VS-Normal |
8.48119999999897E-05 |
| Other-VS-Normal |
1.844640E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.21779996986993E-09 |
| Normal-vs-N1 |
6.91946500097629E-12 |
| N0-vs-N1 |
1.234290E-02 |
|
|
